Pharmaceutical Investing Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
Pharmaceutical Investing ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
Pharmaceutical Investing The One & Only BOTOX® Cosmetic Day Returns November 19 with the Biggest Celebration of the Year
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo
Pharmaceutical Investing Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
pharmaceutical investing Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
Pharmaceutical Investing Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
Pharmaceutical Investing The Confidence Project by BOTOX® Cosmetic Unveils This Year's Grant Recipients
Pharmaceutical Investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Pharmaceutical Investing RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Pharmaceutical Investing Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
